BidaskClub upgraded shares of Orthopediatrics (NASDAQ:KIDS) from a hold rating to a buy rating in a research report report published on Saturday.

Other analysts have also recently issued reports about the stock. ValuEngine upgraded shares of Orthopediatrics from a hold rating to a buy rating in a report on Thursday, August 2nd. William Blair restated an outperform rating on shares of Orthopediatrics in a report on Wednesday, June 27th. Piper Jaffray Companies raised their price target on shares of Orthopediatrics from $24.00 to $30.00 and gave the company an overweight rating in a report on Thursday, July 5th. Finally, Zacks Investment Research cut shares of Orthopediatrics from a hold rating to a strong sell rating in a report on Tuesday, August 14th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $25.67.

Shares of Orthopediatrics stock opened at $30.56 on Friday. Orthopediatrics has a 1 year low of $14.00 and a 1 year high of $31.80. The stock has a market cap of $352.88 million and a price-to-earnings ratio of -5.36. The company has a current ratio of 5.98, a quick ratio of 3.61 and a debt-to-equity ratio of 0.60.

Orthopediatrics (NASDAQ:KIDS) last released its quarterly earnings results on Thursday, August 9th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07). Orthopediatrics had a negative net margin of 61.99% and a negative return on equity of 192.23%. The firm had revenue of $15.10 million during the quarter, compared to the consensus estimate of $14.27 million. The business’s quarterly revenue was up 28.0% on a year-over-year basis. equities research analysts forecast that Orthopediatrics will post -0.8 earnings per share for the current fiscal year.

In other news, Director David R. Pelizzon purchased 2,000 shares of the stock in a transaction dated Tuesday, May 22nd. The shares were acquired at an average cost of $19.50 per share, for a total transaction of $39,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 46.10% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the company. Teachers Advisors LLC purchased a new position in shares of Orthopediatrics in the 4th quarter valued at approximately $102,000. Sei Investments Co. purchased a new position in shares of Orthopediatrics in the 2nd quarter valued at approximately $126,000. TIAA CREF Investment Management LLC purchased a new position in shares of Orthopediatrics in the 4th quarter valued at approximately $130,000. Millennium Management LLC purchased a new position in shares of Orthopediatrics in the 1st quarter valued at approximately $172,000. Finally, Deutsche Bank AG purchased a new position in shares of Orthopediatrics in the 4th quarter valued at approximately $196,000. Institutional investors and hedge funds own 37.66% of the company’s stock.

Orthopediatrics Company Profile

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, locking cannulated blades, locking proximal femurs, spica tables, response spine systems, and pediguards; bandloc, a sub-laminar banding system; and sports medicine and other products, such as anterior cruciate ligament and medial patellofemoral ligament systems.

Featured Article: How Short Selling Works

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.